NP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)
Supply of Hereditary Angioedema Branded Medicines (Cinryze® and Takhzyro®) to NHS Scotland.
Buyer
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Value
£9,461,556
Published
2 May 2025
Closes
2 May 2025
Procurement details
Source
Pcs
Region
Scotland
Procurement method
Limited
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 NP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)
£9,461,556
The Framework Agreement is for the supply of several hereditary angioedema (HAE) branded medicines to NHS Scotland. The Framework Agreement has been awarded as a single supplier framework agreement to one (1) Framework Participant.
Delivery: Scotland
Documents
Unlock document linkNP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)
Not provided
Supply of Hereditary Angioedema Branded Medicines (Cinryze® and Takhzyro®) to NHS Scotland.
Award notice · Web page
NP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)
Not provided
Supply of Hereditary Angioedema Branded Medicines (Cinryze® and Takhzyro®) to NHS Scotland.
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.